

# AMP case report: October 2017 test yourself answers

In the October 2017 issue was a report, "[Primary pulmonary adenocarcinoma with an unusual molecular profile of the EGFR gene at initial presentation](#)," written by members of the Association for Molecular Pathology. Here are answers (in bold) to the three "test yourself" questions that followed that case report.

**1. Precision therapeutic agents are currently FDA approved for lung adenocarcinomas possessing certain mutations/rearrangements in which of the following genes?**

- a) *KRAS*
- b) *EGFR*
- c) *ALK*
- d) a and b

**e) b and c**

**2. Approximately 90 percent of *EGFR* mutations include:**

- a) L861Q and G719X
- b) T790M and L858R
- c) Exon 19 deletions

**d) L858R and exon 19 deletions**

- e) S7681

**3. T790M mutations of the *EGFR* gene:**

- a) are seen only after initial treatment.
- b) can be treated with osimertinib.
- c) have only prognostic significance.
- d) may exist as a germline mutation associated with hereditary lung cancer.

**e) b and d**